AMENDMENTS TO THE CLAIMS

The following list of claims will replace all prior claims in the application:

1. (Currently amended) A compound of formula I



Formula I

wherein

X represents -O-; -S-; -SO-; or -SO_2-;

W is a ~~six-membered, non benzofused, phenyl or heteroaryl ring, substituted by V in *meta* or *para* position~~ non-benzofused phenyl or a six-membered, non-benzofused heteroaryl, wherein the phenyl and heteroaryl are substituted by V in *meta* or *para* position;

V represents a bond; -$(CH_2)_r$-; -A-$(CH_2)_s$-; -CH_2-A-$(CH_2)_t$-; -$(CH_2)_s$-A-; -$(CH_2)_2$-A-$(CH_2)_u$-; -A-$(CH_2)_v$-B-; -CH_2-CH_2-CH_2-A-CH_2-; -A-CH_2-CH_2-B-CH_2-; -CH_2-A-CH_2-CH_2-B-; -CH_2-CH_2-CH_2-A-CH_2-CH_2-; -CH_2-CH_2-CH_2-CH_2-A-CH_2-; -A-CH_2-CH_2-B-CH_2-CH_2-; -CH_2-A-CH_2-CH_2-B-CH_2-; -CH_2-A-CH_2-CH_2-CH_2-B-; -CH_2-CH_2-A-CH_2-CH_2-B-; -O-CH_2-CH(OCH_3)-CH_2-O-; -O-CH_2-CH(CH_3)-CH_2-O-; -O-CH_2-CH(CF_3)-CH_2-O-; -O-CH_2-C(CH_3)$_2$-CH_2-O-; -O-CH_2-C(CH_3)$_2$-O-; -O-C(CH_3)$_2$-CH_2-O-; -O-CH_2-CH(CH_3)-O-; -O-CH(CH_3)-CH_2-O-; -O-CH_2-C(CH_2CH_2)-O-; or -O-C(CH_2CH_2)-CH_2-O-;

A and B independently represent -O-; -S-; -SO-; or -SO_2-;

U represents aryl; or heteroaryl;

T represents -$CONR^1$-; -$(CH_2)_pOCO$-; -$(CH_2)_pN(R^1)CO$-; -$(CH_2)_pN(R^1)SO_2$-; or

-COO-;

Q represents lower alkylene; or lower alkenylene;

M represents hydrogen; cycloalkyl; aryl; heterocyclyl; or heteroaryl;

R^1 represents hydrogen; lower alkyl; lower alkenyl; lower alkinyl; cycloalkyl; aryl; or cycloalkyl-lower alkyl;

p is the integer 1, 2, 3 or 4;

r is the integer 3, 4, 5, or 6;

s is the integer 2, 3, 4, or 5;

t is the integer 1, 2, 3, or 4;

u is the integer 1, 2, or 3; and

v is the integer 2, 3, or 4;

or optically pure enantiomers, racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates, or the meso-form of the compound; or pharmaceutically acceptable salts~~, solvent complexes or morphological forms~~ of the compound.

2. (Currently amended) The compound of formula I according to claim 1, wherein

T represents -$CONR^1$-;

Q represents methylene; and

M represents aryl, or heteroaryl;

or optically pure enantiomers, racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates, or the meso-form of the compound; or pharmaceutically acceptable salts~~, solvent complexes or morphological forms~~ of the compound.

3. (Currently amended) The compound of formula I according to claim 1, wherein V represents $-CH_2CH_2O-$; $-CH_2CH_2CH_2O-$; or $-OCH_2CH_2O-$;

or optically pure enantiomers, racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates, or the meso-form of the compound; or pharmaceutically acceptable salts~~, solvent complexes or morphological forms~~ of the compound.

4. (Currently amended) The compound of formula I according to claim 1, wherein W represents a 1,4-disubstituted phenyl group;

or optically pure enantiomers, diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates, or the meso-form of the compound; or pharmaceutically acceptable salts~~, solvent complexes or morphological forms~~ of the compound.

5. (Currently amended) The compound of formula I according to claim 1, wherein U is a mono-, di-, or trisubstituted phenyl or heteroaryl, whereby the substituents are selected from the group consisting of halogen, lower alkyl, lower alkoxy, and CF_3

or optically pure enantiomers, racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates, or the meso-form of the compound; or pharmaceutically acceptable salts~~, solvent complexes or morphological forms~~ of the compound.

6. (Currently amended) The compound according to claim 1 selected from the group consisting of:

[[(*rac.*)-]](*1R*, 5S**)-7-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-3-oxa-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(3-methoxy-2-methyl-benzyl)amide,

[[(*rac.*)-]](*1R**, *5S**)-7-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-3,3-dioxo-3λ^6-thia-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(2,3-dichlorobenzyl)amide,

[[(*rac.*)-]](*1R**, *3R**, *5S**)-7-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-3-oxo-3λ^4-thia-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(3-methoxy-2-methylbenzyl)amide,

[[(*rac.*)-]](*1R**, *3R**, *5S**)-7-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-3-oxo-3λ^4-thia-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(2-methoxy-3-methylpyridin-4-ylmethyl)amide,

[[(*rac.*)-]](*1R**, *5S**)-7-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-3-oxa-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-[2-(3-hydroxy-propoxy)-3-methylpyridin-4-ylmethyl]amide, and

[[(*rac.*)-]](*1R**, *5S**)-7-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-3,3-dioxo-3λ^6-thia-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-[2-(3-hydroxypropoxy)-3-methylpyridin-4-ylmethyl]amide.

7. (Previously presented) A pharmaceutical composition comprising at least one compound of claim 1 and a carrier and/or an adjuvant.

8-10. (Cancelled).